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Development of severe disease in Plasmodium falciparum malaria infection is thought to be, at least in
part, due to the sequestration of trophozoite-stage infected red blood cells in the microvasculature. The
process of cytoadherence ismediatedbybindingof theparasite protein PfEMP-1on the surfaceof infected
red blood cells to endothelial cell receptors. Although antimalarial treatments rapidly kill parasites, sig-
niﬁcant mortality is still seen in severe malaria, particularly within 24h of hospital admission. We ﬁnd
that cytoadherence of infected red blood cells continues for several hours after killing of the parasite
by antimalarials; after 24h treatment using a range of antimalarials binding is approximately one-thirdalaria
ndothelial
athogenesis
dhesion
CAM-1
rtemisinin
the level of untreated parasite cultures. This is consistent with the maintained presence of PfEMP-1 on
the surface of drug-treated infected red blood cells. A speciﬁc advantage of artesunate over other treat-
ments tested is seen on addition of this drug to younger ring stage parasites, which do not mature to the
cytoadherent trophozoite-stage. These ﬁndings show that cytoadherence, a potential pathogenic prop-
erty of P. falciparum infected red blood cells, continues long after the parasite has been killed. These
ment
uinine
data support the develop
of cytoadherence.
. Introduction
Plasmodium falciparum malaria is responsible for over a million
eaths a year [1] with many of these fatalities occurring in infants
n Africa. An important aspect of the pathogenesis of severemalaria
esults from the ability of infected red blood cells to sequester in
he microvasculature. During the 48h parasite growth stage inside
host red blood cell the parasite makes many changes to the cell.
s well as becoming more metabolically active, and more rigid,
he infected red blood cell becomes capable of adhering to the
ndothelial cells lining the blood vessels [2]. Post-mortem studies
f severemalaria showhigh levels of infected redbloodcells (iRBCs)
ound to microvasculature [3,4]. The involvement of sequestra-
ion in pathogenesis could be directly a result of blocking of the
lood vessels, and/or downstream effects caused by the interaction
Abbreviations: iRBCs, infected red blood cells; PfEMP-1, Plasmodium falciparum
rythrocyte membrane protein 1; DBL, Duffy binding like; ICAM-1, intercellular
dhesion molecule 1; CSA, chondroitin sulphate A; HUVEC, human umbilical vein
ndothelial cells; HDMEC, human dermal microvascular endothelial cells; TNF,
umour necrosis factor; FACS, ﬂuorescence activated cell sorter.
∗ Corresponding author. Current address: Division of Infection and Immunity,
nstitute of Biomedical Life Sciences, Wellcome Centre for Molecular Parasitology,
lasgow Biomedical Research Centre, University of Glasgow, 120 University Place,
lasgow G12 8TA, UK.
E-mail address: k.hughes@bio.gla.ac.uk (K.R. Hughes).
166-6851 © 2009 Published by Elsevier B.V.
oi:10.1016/j.molbiopara.2009.09.007
Open access under CC BY license.of adjunctive therapies to reverse the pathophysiological consequences
© 2009 Published by Elsevier B.V.
between iRBC and the endothelium, including local inﬂammatory
responses [5].
Cytoadherence ismediated by a parasite protein PfEMP-1which
is a large protein comprising several external Duffy-binding-like
(DBL) domains, encoded for by var genes. P. falciparum has around
60 var genes each encoding a PfEMP-1 protein that is probably anti-
genically distinct and may have different cytoadherent properties.
In vitro studies have suggested that each parasite expresses just
one of the 60 PfEMP-1 proteins at a time, although the situation is
less clear in vivo. Switching expressed var gene and hence PfEMP-1
protein, the process of antigenic variation, is a way in which the
parasite may be able to evade recognition by host adaptive anti-
body immune responses. In addition, there is a large variation in
var gene repertoire between individual parasites. The large num-
ber of variants of PfEMP-1 also results in the potential to bind to
many different host receptors [6].
Of the 14 cell adhesion receptors to which iRBC can bind, a
few have been well characterized including ICAM-1, CD36 and
chondroitin sulphate A (CSA). ICAM-1 is of interest as it has been
linked to cerebral malaria [7]. Patients suffering with cerebral
malaria have up-regulated levels of ICAM-1 in the brain and par-
Open access under CC BY license.asite isolates from patients with malaria disease (including those
with CM and compared to asymptomatic infection) showed higher
binding to ICAM-1 protein [8,9]. Although other studies have not
observed such a link [10,11], the ability to adhere to ICAM-1
has been observed in a signiﬁcant proportion of patient isolates
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11,12], and theadhesion interactionhasbeenwell studied [13–15].
D36 is expressed on many types of endothelia (but negligibly
n the brain) and has the ability to bind most patient isolates.
dhesion to endothelium devoid of CD36 may be possible using
latelets expressing CD36 as a bridging interaction [16]. The car-
ohydrate CSA is uniquely implicated in placental adhesion during
regnancy. Parasites able to adhere to CSA express an unusually
onservedPfEMP-1which is expressedduringmalaria inpregnancy
17].
It is known that cytoadherence of iRBC induces signalling events
n endothelial cells [18,19]. Some of these signalling responsesmay
elp protect the host endothelium against damage, as suggested by
he down-regulation of apoptotic genes in endothelial cells [20].
owever, other effects may be damaging. For example, the induc-
ion of ICAM-1 expression on endothelial cells occurs in response
o iRBCs [20], which could lead to further sequestration of iRBC, as
ell as local leukocyte recruitment, amplifying pathology caused
y adhesionor local inﬂammatory responses. There is also evidence
f induction of apoptosis and leakage in endothelial cells following
dhesion of iRBC [21].
Antimalarial treatments are effective at killing parasites where
esistance has not developed; however, there is still a high mortal-
ty rate associated with severe malaria with most deaths occurring
n the ﬁrst 24h after hospital admission [22]. It is clear that even
fter initiation of antimalarial treatment, patients continue toman-
fest worrying clinical signs [22]. It has been suggested that iRBC
fter antimalarial treatment may still continue to cytoadhere—as
bserved in cerebral ultrastructural studies [23]. Furthermore a
otential mechanism for the difference in effectiveness of arte-
unate versus quinine was suggested to be potentially due to
ctivity in preventing sequestration [24]. However, it has not
een shown using in vitro assays to known receptors how anti-
alarial treated iRBC can cytoadhere. We test these hypotheses,
hat non-viable parasites killed by standard antimalarial treat-
ent contribute to disease pathology by their continued ability to
ytoadhere. To investigate this phenomenon, we have performed
n vitro assays for cytoadherence with drug-treated P. falciparum
RBCs to ICAM-1 and human endothelium under both static and
ow conditions.
Using a range of antimalarials we show that non-viable P. falci-
arum iRBCs retain the ability to cytoadhere at least 24h after drug
dministration as a result of the slow rate of degradation of the
urface protein PfEMP-1.
. Materials and methods
.1. Parasite strains and culture
Parasite lines ItG [25] and A4 [26] were used in this study. Both
f these strains are of the IT lineage and are well characterized
or their ability to bind to ICAM-1 and CD36 [14]. ItG was selected
n ICAM-1 protein and expression of the expected var gene con-
rmed by cloning and sequencing a DBL tag from cDNA. A4 was
elected for binding to the monoclonal antibody BC6 [27] followed
y immunoﬂuorescence analysis (IFA) of expressed PfEMP-1 and
equencing of the expressed var tag. Populations used were >80%
omogeneous for the expected var tag. Parasites were cultured
nder standard conditions in RPMI 1640 medium (supplemented
ith 37.5mMHEPES, 7mM d-glucose, 6mM NaOH, 25g/ml gen-
amicin sulphate, 2mM l-glutamine and 10% human serum) at a
H of 7.2, in a gas mixture of 96% nitrogen, 3% carbon dioxide
nd 1% oxygen [28] and synchrony maintained using sorbitol lysis
t ring stages [29]. Two cultures were maintained in parallel 24h
part to allow stage matched controls for 24-h time point experi-
ents.cal Parasitology 169 (2010) 71–78
2.2. Qualitative and quantitative measurement of PfEMP-1 levels
of the surface of P. falciparum A4 iRBCs
PfEMP-1 on the surface of live A4 iRBC was visualised by
immunoﬂuorescence using BC6 monoclonal primary antibody
(1:50 dilution) which speciﬁcally recognises an exposed epitope
of the A4var41 PfEMP-1 [27]. This was followed by a secondary
rabbit anti-mouse antibody (serotec) (1:100) followed by Alexa488
conjugated goat anti-rabbit antibody (molecular probes) (1:5000).
All washes and antibody dilutions were in Dulbecco’s PBS with
1% BSA and each incubation was at 37 ◦C for 30min. Infected
cells were stained with ethidium bromide (1g/ml), mounted on
a microscope slide and analysed by confocal microscopy using
Zeiss LSMPascal microscope and Zeiss Pascal and Photoshop soft-
ware (Adobe). For ﬂow cytometry analysis staining was carried
out as above then infected cells were diluted in PBS and 500,000
events (red blood cells) acquired on Beckman Coulter FACS XL,
gated using forward scatter and side scatter to acquire red blood
cell populations excluding debris and then FL-1 and FL-2 ﬂuores-
cence intensity measured. Analysis was performed using WinMDi
software. Regions were drawn on density plots (i.e. Fig. 4B) of
uninfected controls to gate uninfected cells such that <0.1% of the
population fell into the region classed as ethidium bromide posi-
tive. This region was then used to create a histogram. Region R1
was created for A4var41 positive cells based on negative antibody
controls, <0.1% of the ethidium bromide positive population fell
into region R1 when no primary antibody was included. Similarly
for the antigenically distinct strain ItG <0.1% of the ethidium bro-
mide positive population fell into region R1 (not shown). Themean
ﬂuorescence intensity (MFI) of region R1 was used to quantitate
the level of PfEMP-1 on A4var41 positive infected red blood cells.
The percentage of A4 iRBC that were classed as A4var41 positive
remained at ∼80%.
2.3. Endothelial cells
Human umbilical vein endothelial cells (HUVEC) and human
dermal microvascular endothelial cells (HDMEC) were purchased
from Promocell and cultured as per manufacturer’s instructions.
Cells at passages 4–6 were used for all experiments. Prior to
experimentation cells were stimulated by the addition of 1ng/ml
TNF for 18h. This procedure allowed for the induction of ICAM-
1 expression on the surface of the endothelial cells as veriﬁed
by immunoﬂuorescence microscopy and ﬂow cytometry after
immunoﬂuorescence (data not shown).
2.4. Adhesion assays
All adhesion assays were carried out essentially as previously
described [14]. In brief:
2.5. Flow based protein assays
Aminopropyltriethoxysilane (APES) treated microslides were
coated with ICAM-1-Fc [30] protein at 50g/ml in Dulbecco’s PBS.
Proteinwas allowed to adhere for 2h, then slideswerewashedwith
1% BSA/PBS and blocked in 1% BSA/PBS overnight at 4 ◦C. Parasites
wereprepared to 3%parasitaemia and1%haematocrit (hct) in bind-
ing buffer (RPMI 1640 medium pH 7.2, supplemented with 6mM
glucose). After ﬂowing bindingmedium through themicroslide for
2min, prepared parasites were ﬂowed through at a pump speed of
0.186ml/min, to give a wall shear stress of 0.05Pa (as previously
used [14]) for 5min. Thiswas followedbyﬂowingbindingbuffer for
2min. All assays were carried out at 37 ◦C. Stationary adhered par-
asites were counted in six ﬁelds along the slide. Each experiment
was performed in duplicate or triplicate and on three independent
chemical Parasitology 169 (2010) 71–78 73
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Fig. 1. Phenotype of trophozoite-stage ItG iRBC after artesunate treatment. (A)
Geimsa stained smears of ItG infected red blood cells after 0, 4, 8, and 24h treatmentK.R. Hughes et al. / Molecular & Bio
ccasions. Results shown are compared to 0h control culture, how-
ver an untreated control at equivalentmid-trophozoite-stagewas
sed with each time point and showed no signiﬁcant difference in
ytoadherence compared to 0h control.
.6. Static endothelial cell assays
Endothelial cells cultured as above were seeded onto 13mm
hermanox coverslips (Nunc) coated with 1% gelatin in 24-well
lates. Conﬂuent cells were induced with 1ng/ml TNF for 18h and
ashed in culture medium before an assay. Parasites were pre-
ared to 1% hct and 3% parasitaemia in binding buffer. 0.5ml of
ell suspension was applied to each well and incubated at 37 ◦C for
h with gentle resuspension by rotation every 10min. Unbound
ells were removed by two washes in binding buffer followed by
× 30min gravity washes, in which coverslips were balanced cell
ide down on 0.5ml binding buffer in a 24-well plate at a 45◦ angle
o allow for removal of cells not ﬁrmly adherent. Cells were ﬁxed
ith 1% glutaraldehyde for ≥1h. After staining with 5% Geimsa for
0min, coverslips were washed in water, air dried and mounted
singDPXhard setmountingmedium. 6–10 areas of each cover slip
ere counted for the number of bound parasites. Each experiment
as performed in duplicate or triplicate and on three independent
ccasions. Results shown are compared to 0h control culture, how-
ver an untreated control at equivalentmid-trophozoite-stagewas
sed with each time point and showed no signiﬁcant difference in
ytoadherence compared to 0h control.
.7. Flow based endothelial cell assays
APES treated microslides were coated with 1% gelatin, 1% col-
agen for 45min at 37 ◦C. Endothelial cells at passages 3–5 were
reated with trypsin to detach adherent cells (Promocell detach
it used as per manufacturers’ instructions). Cell suspensions were
pplied to the microslides, and allowed to settle for 2h at 37 ◦C to
orm a conﬂuent monolayer. After overnight growth with media
xchange every hour, TNF (1ng/ml) was added to the conﬂu-
nt cells for 18h before the assay. Parasites were prepared at 3%
arasitaemia and 1% hct in binding buffer. After ﬂowing binding
edium through themicroslide for 2min, prepared parasites were
owed through at a wall shear stress of 0.05Pa for 5min, fol-
owed by a wash with binding buffer (2min). Stationary adherent
arasites were counted in at least six ﬁelds along the slide. Each
xperiment was performed in duplicate or triplicate and on three
ndependent occasions. Results shown are compared to untreated
ontrol culture at equivalent mid-trophozoite-stage for each time
oint.
.8. Drug treatment
The effect of parasite viability on cytoadherence was tested
sing a range of drugs including artesunate, quinine, lumefantrine
nd piperaquine. Final drug concentrations were chosen based on
ublished peak plasma levels. These were: 500nM for artesunate
31,32], 25M for quinine [33,34], 15M for lumefantrine [35,36],
nd 100nM for piperaquine [33,37].
The concentrations of drugs used were well above the IC50
etermined for each (Table 1, supplementary information) and
ere conﬁrmed to inhibit parasite development as assessed by
eimsa staining as described in Section 3. Parasites were con-
rmed non-viable after treatment by continued culture for at least
2h post-treatment with no growth. The minimum exposure time
o 500nM artesunate to stop parasite growth was determined to
e 30min. Various exposure times greater than this followed by
ashing out of the drug did not affect binding phenotype 24h fol-
owing treatment (Supplementary Fig. S1). Drugs were washed outwith 500nM artesunate under culture conditions. (B) Adhesion to ICAM-1 protein
(50g/ml) under ﬂow conditions (0.05Pa shear stress) after 0, 4, 8 or 24h treatment
with 500nM artesunate. Mean of three independent experiments± standard devi-
ation (SD). *P<0.05 and **P<0.01 compared to untreated control (c) trophozoites.
of PRBC cultures immediately prior to adhesion assays (after appro-
priate exposure time as indicated for each experiment) by 2× 5ml
washes in binding buffer before resuspension of culture in bind-
ing buffer. Parasitaemia and haematocrit were counted after drug
exposure before adhesion assays and parasite suspension adjusted
to 3% parasitaemia and 1% haematocrit for each assay.
Growth inhibition (IC50) assays were performed on ItG and A4
parasites using a standard ﬂuorimetric assay [38,39].
2.9. Statistical analysis
Each binding experiment was performed in duplicate or trip-
licate and the mean calculated. Results shown are the mean of
three independent experiments ±SD. Statistical signiﬁcance was
calculated using a two-tailed t-test.
3. Results
3.1. Cytoadherence of artesunate treated P. falciparum ItG iRBCs
to ICAM-1 under ﬂow
Adhesion of P. falciparum ItG iRBC to ICAM-1 protein under ﬂow
was assayed following 4, 8 and 24h artesunate (500nM) treatment
of trophozoites, 24h post-invasion (hpi) stage parasites. Parasite
development as assessed by Geimsa staining appeared to halt after
4h treatment (Fig. 1A) and parasites were noticeably pyknotic fol-
lowing 8h treatment. As described in Section 2, parasites were not
viable for culture following drug treatment.
Cytoadherence of iRBC occurs during the second part of the 48h
intraerythrocytic cycle of the parasite, and no signiﬁcant changes
in the level of cytoadherence of untreated, developing iRBC occur
after adhesion reaches a maximum at 24–26h post-invasion (not
shown). After drug addition to 24hpi iRBC no signiﬁcant difference
in binding was observed for parasites exposed to artesunate for 4h
compared tountreatedparasites (Fig. 1B). Following8h exposure, a
slight reduction in binding was seen and following 24h artesunate
treatment adhesion to ICAM-1was reduced to ∼30% of control lev-
els (P<0.01, Fig. 1). The concentration of artesunate used (500nM)
was chosen as it falls in the normal range reported for observed
plasma concentrations (see Section 2 and Supplementary Table 1),
however, similar binding phenotypeswere observed for artesunate
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Fig. 2. Adhesion of trophozoite-stage ItG iRBC to endothelial cells after 0, 4, 8 or 24h artesunate treatment. Binding under static conditions to (A) HUVEC and (B) HDMEC
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oncentrations ranging from20nMto12.5M(Supplementary Fig.
2).
.2. Cytoadherence of artesunate treated P. falciparum ItG iRBCs
o human endothelial cells
Adhesion of P. falciparum ItG iRBCs to human endothelial cells
HUVEC and HDMEC) was assessed under both static and ﬂow con-
itions following 4, 8 and 24h artesunate (500nM) treatment of
rophozoite (24h post-invasion) stage parasites.
As described in Section 2, binding assays were performed with
onﬂuent monolayers of TNF (1ng/ml, 18h) activated endothelial
ells. Under these conditions HUVEC express the receptor ICAM-1,
hereas HDMEC express both CD36 and ICAM-1.
Under static conditions, there was no signiﬁcant difference in
he level of binding to either HUVEC or HDMEC of P. falciparum
tG iRBCs incubated for 4h with artesunate (500nM) compared to
he untreated controls to (Fig. 2A and B). Following 8h exposure, a
light reduction in binding was seen and following 24h artesunate
reatment adhesion to both HUVEC (P<0.01) and HDMEC (P<0.05)
as reduced to ∼30% of control levels (Fig. 2A and B).
Essentially the same binding phenotypes were observed for
dhesion measured under ﬂow, with up to 8h exposure to arte-
unate (500nM)not signiﬁcantly affecting adhesion to bothHUVEC
r HDMEC, whilst 24h exposure to artesunate (500nM) did reduce
he levels of binding to both cell types to 25–30% of control levels
Fig. 2C and D).
.3. Cytoadherence of other P. falciparum isolates to other
eceptors after artesunate treatment
Similar results to those seen for ItG adhesion after artesunate
reatment were also seen with two other parasite isolates. A4, like
tG, binds to both ICAM-1 and CD36 but generally at lower lev-
ls than ItG [14]. The adhesion of A4 to ICAM-1 protein under
ow and to HDMEC under static conditions was assessed. No sig-
iﬁcant reduction in adhesion was seen after 8h treatment of
rophozoite-stage parasites with artesunate (500nM), however,
fter 24h treatment adhesion was reduced to 25–30% of con-
rols. Additionally the CSA binding strain CS2 [40] was assayed forlial cells. Binding under ﬂow conditions to (C) HUVEC and (D) HDMEC after TNF
ding. Each represents mean of three independent experiments± SD. *P<0.05 and
cytoadherence to CSA protein under ﬂow conditions. No reduc-
tion in adhesion was seen after 8h treatment and signiﬁcant
adhesion at around 25% control levels was observed after 24h
treatment. Experiments after 4 and 24h drug treatment showed
that ItG binding to CD36 was similarly affected (Supplementary
Fig. S3).
3.4. Measurement of PfEMP-1 levels on the surface of
drug-treated P. falciparum iRBCs
To determine whether the continued ability of non-viable para-
sites to adhere is due to the persistence of the PfEMP-1 complex
on the infected erythrocyte membrane, single cell and popula-
tion immunoﬂuorescence measurements were performed using
themonoclonal antibodymAbBC6, speciﬁc for thea surface epitope
of the PfEMP-1 A4var41 variant [26].
Confocal laser scanning microscopy of P. falciparum A4 iRBCs
after immunoﬂuorescent labelling with the primary monoclonal
antibody BC6 revealed the characteristic punctate distribution of
PfEMP-1 on the outer erythrocytic membrane (Fig. 3A). Qualita-
tively, the distribution of PfEMP-1 was not observably different
in P. falciparum iRBCs treated for up to 24h with 500nM arte-
sunate (Fig. 3A). Analysis by ﬂow cytometry conﬁrmed that ∼80%
of iRBCs expressed detectable levels of A4var41 PfEMP-1 (Fig. 3B).
This population percentage did not change through the course of
these experiments. Following treatment with artesunate (500nM,
24h), themean ﬂuorescence of PfEMP-1 surface positive iRBCswas
reduced to approximately 65% the level of untreated cells (P<0.01,
n=3, Fig. 3C and D). Notably, PfEMP-1 could still be detected on
iRBC surface after 4 days treatment (data not shown).
3.5. Cytoadherence of P. falciparum ItG iRBCs to ICAM-1:
comparison of antimalarials
Adhesion of P. falciparum ItG iRBC to ICAM-1 protein under ﬂow
was assayed following 4, 8 and 24h drug treatment of tropho-
zoite (24h post-invasion) stage parasites. The antimalarial drugs
tested were artesunate (500nM), quinine (25M), lumefantrine
(15M) and piperaquine (100nM). As described in Section 2, all
drugs were used at concentrations comparable to published peak
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Fig. 3. Analysis of PfEMP-1 on the surface of live trophozoite-stage A4 iRBC after immunoﬂuorescence using the primary antibody BC6. (A) Confocal ﬂuorescence images of
(i) top plane, and (ii) centre plane of BC6 ﬂuorescence, (iii) ethidium bromide labelling of parasite, and phase contrast images (iv), after 0 (upper) 4 (middle) or 24h (lower)
artesunate treatment. Scale bar (2M) on phase contrast image. (B) Quantitation of PfEMP-1 levels by ﬂow cytometry analysis after BC6 primary antibody and Alexa488
coupled secondary antibody (FL-1, X-axis) and counterstaining infected red blood cellswith ethidiumbromide (FL-2, Y-axis). In the density plots uninfected red blood cells are
the population in the lower left. Box R1 represents BC6 positive infected red blood cells. Plot (i) shows 0h culture, plot (ii) shows the culture after 24h artesunate treatment.
(C) Histogram showing quantitation of BC6 positive ﬂuorescence intensity (X-axis) of the infected population (gated as ethidium bromide positive) untreated trophozoites
(open black) or after artesunate (500nM) 24h (solid red). (D) Mean ﬂuorescence intensity (MFI) for PfEMP-1 positive population (gate R1) mean± SD for three independent
experiments, ** indicates a statistically signiﬁcant difference compared to controls (P<0.01) as determined by T-test. (For interpretation of the references to color in this
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dgure legend, the reader is referred to the web version of the article.)
lasma concentrations andwere conﬁrmed to result in the abroga-
ion of parasite viability.
The binding phenotypes for all treatments were observed to be
ery similar, with no signiﬁcant difference in binding observable
fter 4h drug exposure (Fig. 4A). As observed previously, a small
eduction in bindingwas observed for parasites exposed to 8h arte-
unate (Fig. 4B) but no signiﬁcant difference relative to control cells
as observed for all other drugs (Fig. 4B). A signiﬁcant reduction
n iRBC binding was observed following 24h exposure to all of the
rugs, with binding ∼30% of control levels (Fig. 4C).3.6. Cytoadherence of P. falciparum ItG iRBCs to ICAM-1:
comparison of antimalarials administered to ring stage parasites
As the antimalarial drugs used in this study have different
pharmacodynamic properties, especially in regards to cell cycle
speciﬁcity, binding experiments to ICAM-1 under ﬂow conditions
were repeated as described above but drug exposure was per-
formed on ring stage (12h post-invasion) parasite cultures. These
younger ring stage parasites represent the pre-cytoadherent circu-
lating population.
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Fig. 4. Adhesion of trophozoite-stage ItG iRBC to ICAM-1 protein under ﬂow
conditions after 4h (A), 8 h (B) and 24h (C) treatment with artesunate (art)
(500nM), quinine (quin) (25M), lumefantrine (lum) (15M) or piperaquine
(pip) (100nM). Results are mean of three independent experiments± SD. *P<0.05
and **P<0.01 as determined by T-test compared to untreated control (c) at each
time point. The untreated control for the 24h time point was a stage matched
untreated mid-trophozoite culture indicated by a dotted outline as the untreated
original culture had reinvaded to non-cytoadherent ring stages. There was no
signiﬁcant difference in the adhesion of any of the untreated controls at the
different time points. Treated cultures were dead pyknotic “trophozoite-stage”
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Fig. 5. (A)Geimsa stained smears of ItG iRBC24hafter the additionof indicateddrug
treatment to ring stage (young) parasites. (B) Adhesion to ICAM-1 protein under
ﬂow conditions 24h after addition of treatment to ring stage (young) parasites. The
untreated ring stage control (representing the starting culture) shown at the 24h
timepointwasa stagematcheduntreatedculture indicatedbyadottedoutlineas the
untreated original culture had matured to the cytoadherent trophozoite-stage. A P-arasites.
Adhesion to ICAM-1 protein under ﬂow, was determined after
4h exposure of ring stage P. falciparum ItG iRBCs to artesunate
500nM), quinine (25M), lumefantrine (15M) and piperaquine
100nM) relative to untreated control cells. Signiﬁcant differ-
nces were observed between the various treatments. Artesunate
reated parasites were unable to mature to trophozoites and non-
iable ring parasites were observed after 24h exposure (Fig. 5A),
hilst quinine and lumefantrine treated parasites matured to
ate trophozoites before dying and appearing pyknotic (Fig. 5A).
iperaquine treated parasites appeared to show an intermedi-
te amount of development to late ring/early trophozoite before
ecoming non-viable. Binding experiments revealed that control
arasites allowed to develop for 24h from ring stage para-
ites to trophozoites displayed characteristic levels of adhesion
hilst control ring stage parasites, as expected, displayed a very
ow level of cytoadherence (Fig. 5B). Artesunate treated par-
sites, which as described had failed to mature showed little
ytoadherence, whilst quinine and lumefantrine treated para-
ites displayed high levels of adhesion comparable to control
rophozoite-stage iRBC (Fig. 5B). Treatment of parasiteswith piper-
quine resulted in intermediate levels of binding, ∼50% of control
evels (Fig. 5B).value <0.05was obtained for the comparison between artemisinin treated parasites
and control trophozoites.
4. Discussion
In this study we have assessed the ability of non-viable par-
asites killed by antimalarial treatments to cytoadhere, a process
important in the pathophysiology of disease.
Our data demonstrate that P. falciparum iRBC are capable of
cytoadherence for at least 24h after lethal dosages of a range of
antimalarial drugs. The antimalarial drugs tested in this studywere
artesunate, quinine, lumefantrine and piperaquine at clinically rel-
evant concentrations, chosen to mimic peak plasma drug levels.
The cytoadherence phenotype of iRBCs was measured using both
static and ﬂow assays and using a range of parasite strains (ItG,
A4 and CS2) against puriﬁed receptor proteins (ICAM-1, CD36 and
CSA) and endothelial cells (HUVEC and HDMEC).
These observations are consistentwith observations froma pre-
vious ultrastructural analysis of brains from patients with cerebral
malaria [23] who suggest that they observe morphologically dam-
aged parasites adhered to cerebral endothelium, consistent with
parasite death in situ and maintained adhesion.
Consistent with the continued ability to cytoadhere, we
observed the characteristic punctate distribution of PfEMP-1 on the
surface of P. falciparum iRBC at signiﬁcant levels (∼65% of control)
following 24h antimalarial treatment (Fig. 3).
These data illustrate the stability of the changes made to the
red blood cell by the parasite such that the remodelling of the
infected red blood cells is maintained after the parasite is rendered
non-viable. Nevertheless, quantiﬁcation of the PfEMP-1 levels on
iRBCs surface showed some reduction after drug treatment, con-
sistent with a degree of degradation/loss of the protein. This
reduction in PfEMP-1, combined with potential reduction in other
cytoadherence-related parasite proteins, i.e. KAHRP, could explain
the reduced levels of cytoadherence seen after 24h treatment. This
could be comparable to that seen when mutations are present in
haemoglobin, i.e. haemoglobin C (HbC), and sickle haemoglobin
(HbS). In these cases infected erythrocytes show a slightly reduced
andabnormaldisplayof PfEMP-1andconcurrently reducedcytoad-
herence [41].
chemi
o
d
m
i
c
s
p
a
s
o
i
a
c
t
d
s
s
i
c
t
t
3
v
k
i
o
i
s
t
m
a
a
s
t
s
p
r
i
s
a
p
s
t
f
a
f
t
r
r
t
i
w
i
p
h
p
o
a
t
t
p
[
[
[
[K.R. Hughes et al. / Molecular & Bio
Testing a selection of antimalarial drugs showed that the effect
nmature (24hpost-infection) trophozoite cytoadherencewasnot
rug speciﬁc; the same level of adhesion was seen after 24h treat-
ent with all of the antimalarials tested (Fig. 3).
Previously published data has implied that antimalarial drugs
ncluding quinine, halofantrine, artesunate and artemether reduce
ytoadherence and/or rosetting in P. falciparum [42]. In the Udom-
angpetch et al., study, parasites (presumably ring stage circulating
arasites) were exposed to antimalarial drugs for 2–24h, washed
nd grown in culture until control parasites (no drug expo-
ure) were at late trophozoite/early schizont stage. Depending
n the drug treatment these authors reported a range of bind-
ng phenotypes, most notably parasites exposed to artesunate and
rtemether were reported to result in ≥50% inhibition of both
ytoadherence (static assay) and rosetting. It was concluded by
hese authors that the observed differences between the various
rugs on parasite adhesion probably reﬂected differences in the
usceptibility of asexual stage parasites to antimalarials.
We show a similar effect when drug treatment is added to ring
tage (young) parasites. As shown in Fig. 5A, the various antimalar-
als used inhibited parasite growth at different stages of the asexual
ycle. This is consistent with previous pharmacodynamic data on
he mode of action of these drugs. The minimum exposure time
o artesunate (500nM) to render parasites non-viable was just
0min, reﬂecting the fast mode of action of this drug upon acti-
ation of the endoperoxide bridge [43]. Furthermore the drug is
nown to be active against young ring stage parasites. The activ-
ty of lumefantrine, quinine and piperaquine, however, is based
n the disruption of haeme detoxiﬁcation [44,45] occurring later
n development during haemoglobin digestion by trophozoite-
tage parasites [43,46,47]. The pharmacodynamic differences of
hese drugs when administered to ring stage parasites results in
ismatched comparisons of binding phenotypes. Essentially the
ssays measured the adhesion of dead ring stage parasites for the
rtesunate treatedgroup, against the adhesionof dead trophozoite-
tage parasites for the quinine, lumefantrine and piperaquine
reated groups (Fig. 5A andB). The signiﬁcant reduction in adhesion
een by artesunate treated parasites in Fig. 5 and in the Udomsang-
etch et al., study [42] simply reﬂect that these groups consist of
ing stage parasites that have insufﬁcient levels of binding proteins,
.e. PfEMP-1, exported to the erythrocytemembrane surface at that
tage.
The signiﬁcance of this difference between ring stage acting
rtemisin based treatments and treatments that only act onmature
arasites (i.e. quinine), has also been discussed in the context of the
eaquamat trial. This trial comparedartemisinin andquinine for the
reatment of severe malaria in adults and showed an advantage
or artesunate over quinine, particularly in groups with high par-
sitaemia [24]. The authors suggest that this advantage may stem
rom themechanism of action of artesunate on immature parasites
hereby preventing the next round of sequestration. Our in vitro
esults support that this hypothesis could be valid.
The signiﬁcant observation of our study is that dead parasites
etain the ability to cytoadhere irrespective of the antimalarial
reatment administered. However,we canhypothesise that admin-
stration of fast, ring stage acting antimalarials such as artesunate
ill result in a reduction of de novo cytoadherence when admin-
stered in vivo due to the their ability to prevent maturation of
arasites tomature cytoadherent stages. The persistence of cytoad-
erence for many hours after treatment, despite rapid effects on
arasite viability ﬁts with, and may in part explain, the clinical
bservation of a high mortality rate in ﬁrst 24h after hospital
dmission after initiation of antimalarial treatment [22]. Even
hough treatment is killing the parasites rapidly, we show that
hey would still be able to cytoadhere 24h following treatment,
otentially still contributing to disease pathology.
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It is conceivable that the observed phenomenon of contin-
ued adherence by non-viable P. falciparum iRBCs may be targeted
by adjuvant therapies designed to prevent or preferably reverse
cytoadherence. Indeed, studies have recently been performedwith
Levamisole, which was shown to reduce sequestration of P. falci-
parum in patients by inhibition of CD36 dephosphorylation [48].
In summary, this study has assessed the cytoadherence capa-
bility of drug-killed P. falciparum iRBCs. Our data demonstrate that
non-viable parasites, irrespective of treatment retain the ability to
cytoadhere for up to 24h. This phenomenon is due to the stability of
the changesmade to the host red blood cell by the parasite, as illus-
trated by the continued presence of PfEMP-1 on the surface of iRBC
after loss of parasite viability. This continued capacity for cytoad-
herence could contribute to disease pathology following treatment.
It is hypothesised that fast and ring stage acting antimalarials such
as the endoperoxides may be therapeutically more favourable by
their ability to prevent de novo adhesion, but adjunctive therapy
strategies that can also reverse cytoadherence may also be advan-
tageous in addressing the high mortality seen in severe malaria
early after hospital admission.
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